BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27792697)

  • 1. [Cutaneous manifestations in inflammatory bowel disease].
    Chavez-Álvarez S; Gómez-Flores M; Ocampo-Candiani J
    Gac Med Mex; 2016; 152(5):622-630. PubMed ID: 27792697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cutaneous and mucosal manifestations of inflammatory bowel diseases].
    Károlyi Z; Erós N; Ujszászy L; Nagy G
    Orv Hetil; 2000 Jun; 141(25):1391-5. PubMed ID: 10934882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous Manifestations of Crohn Disease.
    Hagen JW; Swoger JM; Grandinetti LM
    Dermatol Clin; 2015 Jul; 33(3):417-31. PubMed ID: 26143422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease.
    Goldberg I; Finkel O; Gat A; Sprecher E; de Morentin HM
    Isr Med Assoc J; 2014 Mar; 16(3):168-70. PubMed ID: 24761705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatologic manifestations in inflammatory bowel disease in Tunisia.
    Mebazaa A; Aounallah A; Naija N; Cheikh Rouhou R; Kallel L; El Euch D; Boubaker J; Mokni M; Filali A; Ben Osman A
    Tunis Med; 2012 Mar; 90(3):252-7. PubMed ID: 22481199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
    J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of erythema nodosum, aphthous stomatitis, and pyoderma gangrenosum in patients with IBD.
    Tremaine WJ
    Inflamm Bowel Dis; 1998 Feb; 4(1):68-9; discussion 73. PubMed ID: 9552230
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of extraintestinal manifestations of inflammatory bowel disease.
    Grand RJ
    Inflamm Bowel Dis; 1998 Feb; 4(1):72; discussion 73. PubMed ID: 9552233
    [No Abstract]   [Full Text] [Related]  

  • 9. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
    Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
    Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cutaneous symptoms of ulcero-haemorragic rectocolitis and of Crohn's disease (author's transl)].
    Thivolet J; Ortonne JP; Jeune R
    Ann Dermatol Venereol; 1978; 105(8-9):723-7. PubMed ID: 367248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
    Roth N; Biedermann L; Fournier N; Butter M; Vavricka SR; Navarini AA; Rogler G; Scharl M;
    PLoS One; 2019; 14(1):e0210436. PubMed ID: 30682031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do I treat erythema nodosum, aphthous ulcerations, and pyoderma gangrenosum?
    Hanauer SB
    Inflamm Bowel Dis; 1998 Feb; 4(1):70; discussion 73. PubMed ID: 9552231
    [No Abstract]   [Full Text] [Related]  

  • 13. Review article: skin complications associated with inflammatory bowel disease.
    Tavarela Veloso F
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():50-3. PubMed ID: 15352894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
    Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
    J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients.
    Greenstein AJ; Janowitz HD; Sachar DB
    Medicine (Baltimore); 1976 Sep; 55(5):401-12. PubMed ID: 957999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cutaneous manifestations associated with chronic inflammatory bowel disease].
    Farhi D; Cosnes J; Aractingi S; Khosrotehrani K
    Ann Dermatol Venereol; 2009 Nov; 136(11):828-33; 826-7, 834-5. PubMed ID: 19917440
    [No Abstract]   [Full Text] [Related]  

  • 18. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity.
    Dotson JL; Hyams JS; Markowitz J; LeLeiko NS; Mack DR; Evans JS; Pfefferkorn MD; Griffiths AM; Otley AR; Bousvaros A; Kugathasan S; Rosh JR; Keljo D; Carvalho RS; Tomer G; Mamula P; Kay MH; Kerzner B; Oliva-Hemker M; Langton CR; Crandall W
    J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):140-5. PubMed ID: 20453677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease.
    Ciccacci C; Biancone L; Di Fusco D; Ranieri M; Condino G; Giardina E; Onali S; Lepre T; Pallone F; Novelli G; Borgiani P
    J Crohns Colitis; 2013 Feb; 7(1):44-52. PubMed ID: 22445837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
    Vavricka SR; Rogler G; Gantenbein C; Spoerri M; Prinz Vavricka M; Navarini AA; French LE; Safroneeva E; Fournier N; Straumann A; Froehlich F; Fried M; Michetti P; Seibold F; Lakatos PL; Peyrin-Biroulet L; Schoepfer AM
    Inflamm Bowel Dis; 2015 Aug; 21(8):1794-800. PubMed ID: 26020601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.